By Daniella Parra FIGS, Inc. (NYSE: FIGS) said fourth quarter net revenue was $144.9 million and a reclassification negatively impacted net revenues by $4.7 million. Gross margin was 67.5%, a decrease of 70 basis points and operating expenses were $83.6...

By Daniella Parra Vivani Medical, Inc. (Nasdaq: VANI) reported promising preclinical data on NPM-115, a miniature exenatide implant for chronic weight management. The company focuses on GLP-1 implants for obesity treatment due to their potential to improve patient outcomes, which...

By Daniella Parra Vaxxinity, Inc. (Nasdaq: VAXX) said it demonstrated that VXX-401 lowers LDL cholesterol, supporting its potential for treating hypercholesterolemia. The VXX-401, a synthetic peptide vaccine, aims to provide a safe and effective solution against heart disease by targeting...

By Daniella Parra Brii Biosciences and VBI Vaccines (NASDAQ: VBIV) said they will expand and control of BRII-179 supplies, a late-stage asset for HBV functional cure. Initially, a $2.5 million promissory note will be issued, eliminating royalty and milestone payments...

By Daniella Parra Agendia said it has enrolled the first patient using MammaPrint for the Oncology De-Escalation of Breast Radiation (DEBRA) Trial, aiming to reduce breast radiation post-lumpectomy for low-risk, early-stage breast cancer. The trial aims to determine whether hormonal...

By Daniella Parra Vaxxinity, Inc. (Nasdaq: VAXX) said it’s with the University of Florida’s Center for Translational Research in Neurodegenerative Disease (CTRND) to develop vaccines for diseases like Alzheimer’s and Parkinson’s. The collaboration aims to understand and neutralize toxic brain...

By Karen E. Roman Sirnaomics Ltd., a biopharmaceutical company developing RNAi therapeutics, recently published a research article showing a cancer drug candidate to treat solid tumors. The article focused on the company’s clinical studies with STP707, a polypeptide nanoparticle  formulation,...

By Daniella Parra Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) said it showed additional safety and tolerability data, marking the second positive Phase 3 study assessing TNX-102 SL for fibromyalgia management. Tonix said the study met its primary endpoint, demonstrating statistically...

By Karen E. Roman Vaxxinity, Inc. (NASDAQ: VAXX) said it will collaborate with the University of Central Florida in the advancement of space medicine research through a grant funded by the state of Florida. The goal is to further develop...

  By Healthcare Edge Editorial Staff DecisionRx, Inc., a value-based healthcare company focused on minimizing healthcare costs by addressing medication failure, announced a $100 million credit facility from global investment firm Carlyle. Carlyle also obtained an option to acquire 25%...